Skip to main content

Sellas Life Sciences Stock Triples After Cancer Vaccine Data

Bloomberg Markets
17 lis 2026, 17:11Crypto
Oryginał
1 min read

Sellas Life Sciences Group Inc. surged after the drug developer reported positive late-stage trial results for an experimental cancer vaccine to treat an aggressive form of blood cancer.

The company's stock price more than tripled following the announcement of promising data from a late-stage trial for a new cancer vaccine.

Z.ai
Article written by AI
Z.ai GLM-4.7-FlashFree
Free AI articles150 of 150
No limit after signing in with Telegram